Du Y#, Dai J#, Mao L, Wei X, Bai X, Chen L, Lin J, Chi Z, Cui C, Sheng X, Lian B, Tang B, Wang X, Yan X, Li S, Zhou L, Guo J, Chen Y, Si L. Phase Ib study of anlotinib in combination with anti-PD-L1 antibody (TQB2450) in patients with advanced acral melanoma.,J Eur Acad Dermatol Venereol,2024;38(1):93-101.

Xu T#, Dai J#, Tang L, Sun L, Si L, Guo J. Systemic administration of STING agonist promotes myeloid cells maturation and antitumor immunity through regulating hematopoietic stem and progenitor cell fate.,Cancer Immunology, Immunotherapy,2023 Aug 7. doi: 10.1007/s00262-023-03502-7. Epub ahead of print. PMID: 37550427.

Dai J, Bai X, Gao X, et al. Molecular underpinnings of exceptional response in primary malignant melanoma of the esophagus to anti-PD-1 monotherapy.,J Immunother Cancer,11(1):e005937

Mao L#, Dai J#, Cao Y#, Bai X, Sheng X, Chi Z, Cui C, Kong Y, Zhang Y, Wu L, Wang X, Tang B, Lian B, Yan X, Li S, Zhou L, Wei X, Li C, Qi Z, Si L, Guo J. Palbociclib in advanced acral melanoma with genetic aberrations in the cyclin-dependent kinase 4 pathway.,Eur J Cancer,2021 May;148:297-306.

Bai X#, Dai J#, Li C, Cui C, Mao L, Wei X, Sheng X, Chi Z, Yan X, Tang B, Lian B, Wang X, Zhou L, Li S, Kong Y, Qi Z, Xu H, Duan R, Guo J, Si L. Risk models for advanced melanoma patients under anti-PD-1 monotherapy-ad hoc?analyses of pooled data from two clinical trials.,Front Oncol,2021 May 20;11:639085.

Xu T#, Dai J#, Tang L, Yang L, Si L, Sheng X, Cui C, Chi Z, Kong Y, Guo J. EZH2 inhibitor enhances the STING agonist?induced antitumor immunity in melanoma.,J Invest Dermatol,2022;142(4):1158-1170.

肿瘤分子标志物和肿瘤免疫

STING通路调控造血干细胞髓系定向分化及诱导训练免疫的机制研究, 课题负责人, 2024.1.1～2027.12.31, 国家自然科学基金面上项目

KIT基因变异调控黑色素瘤免疫微环境的分子机制及治疗策略研究, 课题负责人, 2021.1.1～2024.12.31, 国家自然科学基金面上项目

外泌体介导的免疫相关膜蛋白在粘膜型黑色素瘤中的功能分析及临床应用价值研究, 课题负责人, 2020.1.1～2022.12.31, 北京市自然科学基金面上项目

新型STING激动剂抗黑色素瘤的作用机制, 课题负责人, 2023.1.1～2024.12.31, 北京市医院管理中心“青苗”人才